BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, July 12, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» In vivo evaluation of CXCR4-targeting radiotracer developed using EPI-X4 analogues
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Diagnostics
In vivo evaluation of CXCR4-targeting radiotracer developed using EPI-X4 analogues
Oct. 24, 2022
No Comments
Rational drug design based on EPI-X4, endogenous antagonist of C-X-C motif chemokine receptor (CXCR4), led to the identification of optimized analogues named JMF-01 to JMF-07, which demonstrated increased antagonistic activity.
BioWorld Science
Conferences
Cancer
Diagnostics
Imaging